Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Jul;149(1):293–305.

Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

D R Senger 1, S R Ledbetter 1, K P Claffey 1, A Papadopoulos-Sergiou 1, C A Peruzzi 1, M Detmar 1
PMCID: PMC1865227  PMID: 8686754

Abstract

We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.

Full text

PDF
297

Images in this article

297Figure 1
on p.297
297Figure 2
on p.297
299Figure 4
on p.299

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480–1487. doi: 10.1056/NEJM199412013312203. [DOI] [PubMed] [Google Scholar]
  2. Akiyama S. K., Yamada S. S., Chen W. T., Yamada K. M. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol. 1989 Aug;109(2):863–875. doi: 10.1083/jcb.109.2.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Banai S., Shweiki D., Pinson A., Chandra M., Lazarovici G., Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994 Aug;28(8):1176–1179. doi: 10.1093/cvr/28.8.1176. [DOI] [PubMed] [Google Scholar]
  4. Bauer J. S., Schreiner C. L., Giancotti F. G., Ruoslahti E., Juliano R. L. Motility of fibronectin receptor-deficient cells on fibronectin and vitronectin: collaborative interactions among integrins. J Cell Biol. 1992 Jan;116(2):477–487. doi: 10.1083/jcb.116.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bendixen E., Borth W., Harpel P. C. Transglutaminases catalyze cross-linking of plasminogen to fibronectin and human endothelial cells. J Biol Chem. 1993 Oct 15;268(29):21962–21967. [PubMed] [Google Scholar]
  6. Beninati S., Senger D. R., Cordella-Miele E., Mukherjee A. B., Chackalaparampil I., Shanmugam V., Singh K., Mukherjee B. B. Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. J Biochem. 1994 Apr;115(4):675–682. doi: 10.1093/oxfordjournals.jbchem.a124395. [DOI] [PubMed] [Google Scholar]
  7. Berkman R. A., Merrill M. J., Reinhold W. C., Monacci W. T., Saxena A., Clark W. C., Robertson J. T., Ali I. U., Oldfield E. H. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 1993 Jan;91(1):153–159. doi: 10.1172/JCI116165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brooks P. C., Clark R. A., Cheresh D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22;264(5158):569–571. doi: 10.1126/science.7512751. [DOI] [PubMed] [Google Scholar]
  9. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157–1164. doi: 10.1016/0092-8674(94)90007-8. [DOI] [PubMed] [Google Scholar]
  10. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Dvorak H. F., Senger D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993 Nov;143(5):1255–1262. [PMC free article] [PubMed] [Google Scholar]
  11. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993 Oct 1;53(19):4727–4735. [PubMed] [Google Scholar]
  12. Brown L. F., Harrist T. J., Yeo K. T., Ståhle-Bäckdahl M., Jackman R. W., Berse B., Tognazzi K., Dvorak H. F., Detmar M. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol. 1995 May;104(5):744–749. doi: 10.1111/1523-1747.ep12606974. [DOI] [PubMed] [Google Scholar]
  13. Brown L. F., Olbricht S. M., Berse B., Jackman R. W., Matsueda G., Tognazzi K. A., Manseau E. J., Dvorak H. F., Van de Water L. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol. 1995 Mar 15;154(6):2801–2807. [PubMed] [Google Scholar]
  14. Brown L. F., Papadopoulos-Sergiou A., Berse B., Manseau E. J., Tognazzi K., Perruzzi C. A., Dvorak H. F., Senger D. R. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994 Sep;145(3):610–623. [PMC free article] [PubMed] [Google Scholar]
  15. Brown L. F., Yeo K. T., Berse B., Yeo T. K., Senger D. R., Dvorak H. F., van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992 Nov 1;176(5):1375–1379. doi: 10.1084/jem.176.5.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cheresh D. A., Spiro R. C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987 Dec 25;262(36):17703–17711. [PubMed] [Google Scholar]
  17. Claffey K. P., Brown L. F., del Aguila L. F., Tognazzi K., Yeo K. T., Manseau E. J., Dvorak H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996 Jan 1;56(1):172–181. [PubMed] [Google Scholar]
  18. Claffey K. P., Wilkison W. O., Spiegelman B. M. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem. 1992 Aug 15;267(23):16317–16322. [PubMed] [Google Scholar]
  19. Connolly D. T., Heuvelman D. M., Nelson R., Olander J. V., Eppley B. L., Delfino J. J., Siegel N. R., Leimgruber R. M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989 Nov;84(5):1470–1478. doi: 10.1172/JCI114322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Davis G. E. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1025–1031. doi: 10.1016/0006-291x(92)91834-d. [DOI] [PubMed] [Google Scholar]
  21. Denhardt D. T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993 Dec;7(15):1475–1482. [PubMed] [Google Scholar]
  22. Detmar M., Imcke E., Ruszczak Z., Orfanos C. E. Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. J Invest Dermatol. 1990 Dec;95(6 Suppl):219S–222S. doi: 10.1111/1523-1747.ep12875807. [DOI] [PubMed] [Google Scholar]
  23. Detmar M., Yeo K. T., Nagy J. A., Van de Water L., Brown L. F., Berse B., Elicker B. M., Ledbetter S., Dvorak H. F. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol. 1995 Jul;105(1):44–50. doi: 10.1111/1523-1747.ep12312542. [DOI] [PubMed] [Google Scholar]
  24. Diamond M. S., Springer T. A. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994 Jun 1;4(6):506–517. doi: 10.1016/s0960-9822(00)00111-1. [DOI] [PubMed] [Google Scholar]
  25. Drake C. J., Cheresh D. A., Little C. D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995 Jul;108(Pt 7):2655–2661. doi: 10.1242/jcs.108.7.2655. [DOI] [PubMed] [Google Scholar]
  26. Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995 May;146(5):1029–1039. [PMC free article] [PubMed] [Google Scholar]
  27. Dvorak H. F., Senger D. R., Dvorak A. M., Harvey V. S., McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985 Mar 1;227(4690):1059–1061. doi: 10.1126/science.3975602. [DOI] [PubMed] [Google Scholar]
  28. Fava R. A., Olsen N. J., Spencer-Green G., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Senger D. R., Dvorak H. F., Brown L. F. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994 Jul 1;180(1):341–346. doi: 10.1084/jem.180.1.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ferrara N., Henzel W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989 Jun 15;161(2):851–858. doi: 10.1016/0006-291x(89)92678-8. [DOI] [PubMed] [Google Scholar]
  30. Ferrara N., Houck K., Jakeman L., Leung D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992 Feb;13(1):18–32. doi: 10.1210/edrv-13-1-18. [DOI] [PubMed] [Google Scholar]
  31. Fitzgerald L. A., Poncz M., Steiner B., Rall S. C., Jr, Bennett J. S., Phillips D. R. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry. 1987 Dec 15;26(25):8158–8165. doi: 10.1021/bi00399a021. [DOI] [PubMed] [Google Scholar]
  32. Fitzgerald L. A., Steiner B., Rall S. C., Jr, Lo S. S., Phillips D. R. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". J Biol Chem. 1987 Mar 25;262(9):3936–3939. [PubMed] [Google Scholar]
  33. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  34. Gospodarowicz D., Abraham J. A., Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7311–7315. doi: 10.1073/pnas.86.19.7311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992 Apr 3;69(1):11–25. doi: 10.1016/0092-8674(92)90115-s. [DOI] [PubMed] [Google Scholar]
  36. Imcke E., Ruszczak Z., Mayer-da Silva A., Detmar M., Orfanos C. E. Cultivation of human dermal microvascular endothelial cells in vitro: immunocytochemical and ultrastructural characterization and effect of treatment with three synthetic retinoids. Arch Dermatol Res. 1991;283(3):149–157. doi: 10.1007/BF00372054. [DOI] [PubMed] [Google Scholar]
  37. Kiefer M. C., Bauer D. M., Barr P. J. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res. 1989 Apr 25;17(8):3306–3306. doi: 10.1093/nar/17.8.3306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  39. Klein S., Giancotti F. G., Presta M., Albelda S. M., Buck C. A., Rifkin D. B. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell. 1993 Oct;4(10):973–982. doi: 10.1091/mbc.4.10.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Klemke R. L., Yebra M., Bayna E. M., Cheresh D. A. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994 Nov;127(3):859–866. doi: 10.1083/jcb.127.3.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  42. Leavesley D. I., Ferguson G. D., Wayner E. A., Cheresh D. A. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol. 1992 Jun;117(5):1101–1107. doi: 10.1083/jcb.117.5.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Liaw L., Almeida M., Hart C. E., Schwartz S. M., Giachelli C. M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994 Feb;74(2):214–224. doi: 10.1161/01.res.74.2.214. [DOI] [PubMed] [Google Scholar]
  44. Liaw L., Skinner M. P., Raines E. W., Ross R., Cheresh D. A., Schwartz S. M., Giachelli C. M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995 Feb;95(2):713–724. doi: 10.1172/JCI117718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Martinez J., Chalupowicz D. G., Roush R. K., Sheth A., Barsigian C. Transglutaminase-mediated processing of fibronectin by endothelial cell monolayers. Biochemistry. 1994 Mar 8;33(9):2538–2545. doi: 10.1021/bi00175a024. [DOI] [PubMed] [Google Scholar]
  46. Millauer B., Wizigmann-Voos S., Schnürch H., Martinez R., Møller N. P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993 Mar 26;72(6):835–846. doi: 10.1016/0092-8674(93)90573-9. [DOI] [PubMed] [Google Scholar]
  47. Miyamoto S., Akiyama S. K., Yamada K. M. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science. 1995 Feb 10;267(5199):883–885. doi: 10.1126/science.7846531. [DOI] [PubMed] [Google Scholar]
  48. Monacci W. T., Merrill M. J., Oldfield E. H. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol. 1993 Apr;264(4 Pt 1):C995–1002. doi: 10.1152/ajpcell.1993.264.4.C995. [DOI] [PubMed] [Google Scholar]
  49. Murry C. E., Giachelli C. M., Schwartz S. M., Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. 1994 Dec;145(6):1450–1462. [PMC free article] [PubMed] [Google Scholar]
  50. Mustonen T., Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 1995 May;129(4):895–898. doi: 10.1083/jcb.129.4.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Pepper M. S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991 Dec 16;181(2):902–906. doi: 10.1016/0006-291x(91)91276-i. [DOI] [PubMed] [Google Scholar]
  52. Peters K. G., De Vries C., Williams L. T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8915–8919. doi: 10.1073/pnas.90.19.8915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pierce E. A., Avery R. L., Foley E. D., Aiello L. P., Smith L. E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905–909. doi: 10.1073/pnas.92.3.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Prince C. W., Dickie D., Krumdieck C. L. Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1205–1210. doi: 10.1016/0006-291x(91)90669-x. [DOI] [PubMed] [Google Scholar]
  55. Pötgens A. J., Lubsen N. H., van Altena M. C., Schoenmakers J. G., Ruiter D. J., de Waal R. M. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol. 1995 Jan;146(1):197–209. [PMC free article] [PubMed] [Google Scholar]
  56. Quinn T. P., Peters K. G., De Vries C., Ferrara N., Williams L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533–7537. doi: 10.1073/pnas.90.16.7533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Rodan G. A. Osteopontin overview. Ann N Y Acad Sci. 1995 Apr 21;760:1–5. doi: 10.1111/j.1749-6632.1995.tb44614.x. [DOI] [PubMed] [Google Scholar]
  58. Ruoslahti E., Noble N. A., Kagami S., Border W. A. Integrins. Kidney Int Suppl. 1994 Jan;44:S17–S22. [PubMed] [Google Scholar]
  59. Schwartz M. A., Denninghoff K. Alpha v integrins mediate the rise in intracellular calcium in endothelial cells on fibronectin even though they play a minor role in adhesion. J Biol Chem. 1994 Apr 15;269(15):11133–11137. [PubMed] [Google Scholar]
  60. Semenkovich C. F., Ostlund R. E., Jr, Olson M. O., Yang J. W. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry. 1990 Oct 16;29(41):9708–9713. doi: 10.1021/bi00493a028. [DOI] [PubMed] [Google Scholar]
  61. Senger D. R., Brown L. F., Perruzzi C. A., Papadopoulos-Sergiou A., Van de Water L. Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci. 1995 Apr 21;760:83–100. doi: 10.1111/j.1749-6632.1995.tb44622.x. [DOI] [PubMed] [Google Scholar]
  62. Senger D. R., Connolly D. T., Van de Water L., Feder J., Dvorak H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990 Mar 15;50(6):1774–1778. [PubMed] [Google Scholar]
  63. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985. doi: 10.1126/science.6823562. [DOI] [PubMed] [Google Scholar]
  64. Senger D. R., Perruzzi C. A., Gracey C. F., Papadopoulos A., Tenen D. G. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988 Oct 15;48(20):5770–5774. [PubMed] [Google Scholar]
  65. Senger D. R., Perruzzi C. A., Papadopoulos-Sergiou A., Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 1994 May;5(5):565–574. doi: 10.1091/mbc.5.5.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Senger D. R., Perruzzi C. A., Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989 Sep-Oct;9(5):1291–1299. [PubMed] [Google Scholar]
  67. Senger D. R., Perruzzi C. A., Papadopoulos A., Tenen D. G. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta. 1989 Jun 13;996(1-2):43–48. doi: 10.1016/0167-4838(89)90092-7. [DOI] [PubMed] [Google Scholar]
  68. Sepp N. T., Li L. J., Lee K. H., Brown E. J., Caughman S. W., Lawley T. J., Swerlick R. A. Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol. 1994 Sep;103(3):295–299. doi: 10.1111/1523-1747.ep12394617. [DOI] [PubMed] [Google Scholar]
  69. Somerman M. J., Berry J. E., Khalkhali-Ellis Z., Osdoby P., Simpson R. U. Enhanced expression of alpha v integrin subunit and osteopontin during differentiation of HL-60 cells along the monocytic pathway. Exp Cell Res. 1995 Feb;216(2):335–341. doi: 10.1006/excr.1995.1042. [DOI] [PubMed] [Google Scholar]
  70. Sriramarao P., Mendler M., Bourdon M. A. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci. 1993 Aug;105(Pt 4):1001–1012. doi: 10.1242/jcs.105.4.1001. [DOI] [PubMed] [Google Scholar]
  71. Takeshita S., Zheng L. P., Brogi E., Kearney M., Pu L. Q., Bunting S., Ferrara N., Symes J. F., Isner J. M. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994 Feb;93(2):662–670. doi: 10.1172/JCI117018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., Armellino D. C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579–1586. doi: 10.1016/0006-291x(92)90483-2. [DOI] [PubMed] [Google Scholar]
  73. Warren R. S., Yuan H., Matli M. R., Gillett N. A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995 Apr;95(4):1789–1797. doi: 10.1172/JCI117857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Weindel K., Moringlane J. R., Marmé D., Weich H. A. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery. 1994 Sep;35(3):439–449. doi: 10.1227/00006123-199409000-00012. [DOI] [PubMed] [Google Scholar]
  75. Wilting J., Christ B., Bokeloh M., Weich H. A. In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Tissue Res. 1993 Oct;274(1):163–172. doi: 10.1007/BF00327997. [DOI] [PubMed] [Google Scholar]
  76. Yamada K. M., Kennedy D. W., Yamada S. S., Gralnick H., Chen W. T., Akiyama S. K. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. Cancer Res. 1990 Aug 1;50(15):4485–4496. [PubMed] [Google Scholar]
  77. Yeo K. T., Wang H. H., Nagy J. A., Sioussat T. M., Ledbetter S. R., Hoogewerf A. J., Zhou Y., Masse E. M., Senger D. R., Dvorak H. F. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993 Jun 15;53(12):2912–2918. [PubMed] [Google Scholar]
  78. de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992 Feb 21;255(5047):989–991. doi: 10.1126/science.1312256. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES